Document Detail

Determination of the time for maximal response to neoadjuvant hormone therapy for prostate cancer using magnetic resonance with spectroscopy (MRSI) and dynamic contrast enhancement (DCEMR).
MedLine Citation:
PMID:  21396849     Owner:  NLM     Status:  Publisher    
PURPOSE:: To determine the time-dependent metabolic and angiogenic changes that occur in prostate cancer (CaP) during neoadjuvant hormone therapy (HT), using a combination of MRSI and DCEMR analysis. MATERIALS AND METHODS:: This is a prospective study on a population of non-metastatic CaP submitted to neoadjuvant HT prior to radiation therapy. All cases homogeneously received a 6-month period of neoadjuvant HT using leuprorelin acetate 7.5 mg every 28 days. In all cases, a MRSI/DCEMR study was performed at baseline (pretreatment) and at regular intervals (4, 12, 24 weeks) during HT. Serum PSA was measured at baseline and at the same intervals (4, 12, 24 weeks). All MRI examinations were performed on a commercially available 3 T scanner. RESULTS:: There was a significant ( P < 0.01) time-dependent loss of all prostate metabolites during HT. In regions of CaP no significant variation in the absolute value of metabolites was reported at 1-month interval and a higher variation was observed at 24-week compared with 12-week interval. A complete metabolic atrophy was a common feature (30%) at a 24-week interval of HT, but not at short (4-week 0%), and lower at an intermediate interval (12-week 10%). At DCEMR, onset time and time to peak parameters significantly (P < 0.05) increased at 12- and 24-week intervals. CONCLUSIONS:: To individualize neoadjuvant HT courses prior to definitive treatment, the combination of MRSI and DCEMR may represent a valid noninvasive method, and the addition to PSA data could be used to better assess the time-dependent efficacy of HT in our patients.
Alessandro Sciarra; Valeria Panebianco; Stefano Salciccia; Danilo Lisi; Andrea Alfarone; Alessandro Gentilucci; Ulderico Parente; Susanna Cattarino; Roberto Passariello; Vincenzo Gentile
Related Documents :
22373499 - Effect of feedback on delaying deterioration in quality of compressions during 2 minute...
22286599 - A case-controlled evaluation of the medtronic resting heart system compared with conven...
22418879 - Quantifying the extent of fistulotomy. how much sphincter can we safely divide? a three...
21346349 - Score for the targeting of atrial fibrillation: a new approach to diagnosing paroxysmal...
20156769 - Co-trimoxazole and prevention of relapses of pr3-anca positive vasculitis with pulmonar...
22672099 - Intraoperative neurophysiologic methods for spinal cord stimulator placement under gene...
20074159 - Comparison of temporary stent insertion with pneumatic dilation of the same diameter in...
16684019 - Predictors of appropriate defibrillator therapy among patients with an implantable defi...
22835079 - The efficacy of parecoxib on systemic inflammatory response associated with cardiopulmo...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-9
Journal Detail:
Title:  Urologic oncology     Volume:  -     ISSN:  1873-2496     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9805460     Medline TA:  Urol Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 Elsevier Inc. All rights reserved.
Department of Urology, University Sapienza of Rome, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Noninfiltrative anesthesia for transrectal prostate biopsy: A randomized prospective study comparing...
Next Document:  Utility of (18)F-FDG PET/CT in identifying penile squamous cell carcinoma metastatic lymph nodes.